Cancer Stem Cell News Volume 9.40 | Oct 21 2020

    0
    34







    2020-10-21 | Volume 9.40


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 9.40 – 21 October, 2020
    TOP STORY

    WNT11-FZD7-DAAM1 Signaling Supports Tumor Initiating Abilities and Melanoma Amoeboid Invasion

    Investigators showed that WNT11-FZD7-DAAM1 activated Rho-ROCK1/2-Myosin II and played a crucial role in regulating tumour-initiating potential, local invasion and distant metastasis formation.
    [Nature Communications]

    Full ArticlePress Release

    Survey Report: Where Is Pluripotent Stem Cell Research Now?
    PUBLICATIONSRanked by the impact factor of the journal

    Exploiting
    Oxidative Phosphorylation to Promote the Stem and Immunoevasive Properties of Pancreatic Cancer Stem Cells

    Researchers describe a 2D in vitro system for long-term enrichment of pancreatic CSCs that was amenable to biological and CSC-specific studies.
    [Nature Communications]

    Full Article

    Nanoparticle-Delivered
    Miriplatin Ultrasmall Dots Suppress Triple Negative Breast Cancer Lung Metastasis by Targeting Circulating Tumor Cells

    The authors found that ultrasmall Pt(II) dot active targeting nanoparticles displayed a superior DNA damage capability via enhanced-interactions with DNA and a significantly stronger effect in reducing CSC-like property of triple negative breast cancer cells, compared to conventional cisplatin and miriplatin.
    [Journal of Controlled Release]

    Full ArticleGraphical Abstract

    Tenascin C Promotes Cancer Cell Plasticity in Mesenchymal Glioblastoma

    Researchers identified Tenascin C (TNC) to be upregulated and secreted in mesenchymal glioblastoma subtype with high NF-κB signaling activity. Silencing TNC decreased proliferation, migration and suppresses self-renewal of glioma stem cells.
    [Oncogene]

    Abstract

    SMAR1
    Repression by Pluripotency Factors and Consequent Chemoresistance in Breast Cancer Stem-Like Cells Is Reversed by Aspirin

    Investigators found in breast tumors that the expression of SMAR1 was decreased in CSCs through the cooperative interaction of the pluripotency factors Oct4 and Sox2 with the histone deacetylase HDAC1.
    [Science SIgnaling]

    Full Article

    Melanoma
    Stem Cell-Like Phenotype and Significant Suppression of Immune Response within a Tumor Are Regulated by TRIM28 Protein

    TRIM28 high level related to higher melanoma stemness as measured with several distinct scores and TRIM28HIGH-expressing melanoma cell lines possess the greater potential of melanosphere formation.
    [Cancers]

    Full Article

    TGFBI Modulates Tumor Hypoxia and Promotes Breast Cancer Metastasis

    Researchers crossed the MMTV‐PyMT model of mammary gland tumourigenesis with a TgfbiΔ/Δ mouse, and studied the CSC content of the tumors. We performed RNAseq on wt and ko tumours, and analysed the tumour vasculature and the immune compartment by IHC and FACS.
    [Molecular Oncology]

    Abstract

    Pharmacological
    Ascorbate Inhibits Pancreatic Cancer Metastases via a Peroxide-Mediated Mechanism

    Several in vitro and in vivo mechanisms involved in pancreatic cancer (PDAC) metastases were investigated following treatment with P-AscH. Serum from PDAC patients in clinical trials with P-AscH were tested for the presence and quantity of circulating tumor cell-derived nucleases.
    [Scientific Reports]

    Full Article

    IL-8/CXCR2
    Mediates Tropism of Human Bone Marrow-Derived Mesenchymal Stem Cells toward CD133+/CD44+ Colon Cancer Stem Cells

    Scientists compared the effects of three tissue‐derived mesenchynal stem cells (MSCs) in vivo on colon tumor xenograft growth. Then, they analyzed the tropism of bone marrow‐derived MSCs toward normal intestinal epithelial cells, parental colon cancer cells, CD133−/CD44−, and CD133+/CD44+ colon cancer cells in vitro.
    [Journal of Cellular Physiology]

    Abstract


    Free E-Book: Genome Editing Applications for Disease Modeling and Cell Therapy.
    REVIEWS

    Practical
    Classification of Triple-Negative Breast Cancer: Intratumoral Heterogeneity, Mechanisms of Drug Resistance, and Novel Therapies

    Despite several efforts, transcriptomic and genomic classifications have remained merely theoretic and most of the patients are being treated with chemotherapy. Driver alterations in potentially targetable genes, including PIK3CA and AKT, have been identified across triple negative breast cancer subtypes, prompting the implementation of biomarker-driven therapeutic approaches.
    [npj breast cancer]

    Full Article

    DYRK2 Controls a Key Regulatory Network in Chronic Myeloid Leukemia Stem Cells

    Scientists discuss molecular maintenance in leukemia stem cells in chronic myeloid leukemia and provide a more in-depth discussion of the dual-specificity kinase DYRK2, which has been identified as a novel actionable checkpoint in a critical leukemic network.
    [Experimental and Molecular Medicine]

    Full Article
    INDUSTRY AND POLICY NEWS

    FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

    Merck announced that the FDA has approved an expanded label for KEYTRUDA®, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
    [Merck & Co., Inc.]

    Press Release

    Agios
    Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

    Agios Pharmaceuticals, Inc. announced the withdrawal of its European Marketing Authorization Application for TIBSOVO® for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation.
    [Agios Pharmaceuticals, Inc]

    Press Release
    FEATURED EVENT

    The
    Evolving Tumor Microenvironment In Cancer Progression: Mechanisms And Emerging Therapeutic Opportunities

    January 11 – January 12, 2021
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Senior Researcher – Translational Medicine and Therapeutics for Leukemia

    Karolinska Institutet – Flemingsberg, Sweden

    Clinical
    Research Associate – Hematology, Oncology, and Bone Marrow Transplantation

    The University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral
    Scientists – Stem Cell Factors in Epithelial Cancers

    The University of Chicago – Chicago, Illinois, United States

    Assistant/Associate
    Professor – Center for Molecular Medicine

    The University of Georgia – Athens, Georgia, United States

    Postdoctoral Position – Human Pluripotent Stem Cells, Hematopoiesis and Leukemia

    Icahn School of Medicine at Mount Sinai – New York City, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cancer Stem Cell News
    Archives Contact Us
    Cancer Stem Cell News Twitter